	US 12,285,539 B2
	Hemostatic compositions and related methods
Lauren Lydecker, Millbury, MA (US); Poorva Rajguru, Shoreview, MN (US); David Wulfman, Minneapolis, MN (US); and Joseph Rausa, Littleton, MA (US)
Assigned to Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed by Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed on Apr. 16, 2021, as Appl. No. 17/233,101.
Claims priority of provisional application 63/011,492, filed on Apr. 17, 2020.
Prior Publication US 2021/0322629 A1, Oct. 21, 2021
Int. Cl. A61L 26/00 (2006.01); C08K 3/011 (2018.01); C08K 3/32 (2006.01); C08L 5/08 (2006.01)

CPC A61L 26/0023 (2013.01) [A61L 26/0076 (2013.01); A61L 26/0085 (2013.01); C08K 3/011 (2018.01); C08K 3/32 (2013.01); C08L 5/08 (2013.01); A61L 2400/04 (2013.01); C08K 2003/324 (2013.01)]

12 Claims

1. A method of preparing a composition, the method comprising:

electrospraying a solution consisting essentially of a chitosan salt through a needle into an aqueous solution comprising a crosslinking agent to produce a plurality of particles comprising chitosan and the crosslinking agent; and

freeze drying the plurality of particles;

wherein the solution has a viscosity at 25° C. ranging from about 1,500 cPs to about 8,000 cPs; wherein the crosslinking agent comprises tripolyphosphate; wherein the plurality of particles have an average diameter ranging from about 100 μm to about 750 μm and an average aspect ratio ranging from about 0.6 to 1.0; and wherein the plurality of particles has a porosity greater than 80%, as measured by mercury intrusion porosimetry.